TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05019287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic human menstrual blood stem cells secretome
Description: This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous saline injection
Description: Intravenous saline injection in addition to standard care
Study: NCT05529966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NGENUITY
Description: Device for 3-D viewing during placement of micro-stent placement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional microscope
Description: Device for stereoscopic viewing during placement of micro-stent placement.
Study: NCT05899907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: 160mg once a week for 48 weeks
Study: NCT03063190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: patients will receive vitamin D supplementation according to guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: patients will receive vitamin D supplementation according to guidelines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: patients will receive placebo oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: patients will receive placebo oral tablets
Study: NCT05223387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axiom TL REG
Description: Anthogyr AXIOM TL Reg will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Axiom BL REG
Description: Axiom BL Reg implants will be placed in healed bone crests in the mandible or maxilla for multiple teeth replacement, followed by a provisional prosthesis immediately loaded, if the patient needs a provisional.~In each case, the MU abutment will be placed immediately after implant placement.~Multi-Unit abutments are used to fix the prosthesis
Study: NCT04817293

Intervention type: OTHER
Intervention: medical consultation
Description: Medical consultation during the visit with data collection
Study: NCT04814771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] TS-142
Description: Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution
Study: NCT06632366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Dysfunction in the Postpartum Period
Description: The experimental group will receive mindfulness-based self-compassion training. The control group will not receive any intervention.
Study: NCT06123455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine
Description: Taurine supplementation in capsules of 1.0 gram of taurine powder. Dosage: 2.0 gram/day. Frequency: 2 time/day.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX regimen
Description: Oxaliplatin + capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX regimen
Description: Oxaliplatin + capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX regimen
Description: Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX regimen
Description: Oxaliplatin + S-1 (tegafur/gimeracil/oteracil potassium)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Oxaliplatin + leucovorin + fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Oxaliplatin + leucovorin + fluorouracil
Study: NCT05774886

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Implantable Microdevice (IMD)
Description: * Small, implantable device with 30 reservoirs for drug and drug combinations.~* Placement of 2 microdevices into tumor will be performed via needle, percutaneously, and guided by interventional radiologic techniques.~* Drugs include all or a subset of the following: Doxorubicin, Paclitaxel, Carboplatin, Eribulin, Pembrolizumab, Atezolizumab, Tazemetostat, Panobinostat, Olaparib, Capecitabine, Sacituzumab govitecan, Abemaciclib, Venetoclax, Doxorubicin + cyclophosphamide (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin (combination), Carboplatin + paclitaxel (combination), Doxorubicin + cyclophosphamide + pembrolizumab (combination), Doxorubicin + cyclophosphamide + paclitaxel + carboplatin + Pembrolizumab (combination), Paclitaxel + atezolizumab (combination), Paclitaxel + pembrolizumab (combination), Carboplatin + gemcitabine + pembrolizumab (combination), Carboplatin + paclitaxel + pembrolizumab (combination), Trastuzumab deruxtecan
Study: NCT04378296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teledermatology
Description: The experimental group will be made up of dermatological patients monitored asynchronously.
Study: NCT05226611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counterstrain
Description: Counterstrain is a hands-on OMM technique that involves shortening the muscle to resolve the dysfunctional muscle stretch reflex and holding it for 90 seconds. The patient is then brought back to a neutral position and reassessed.
Study: NCT06386705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN084
Description: TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN084
Description: TSN084 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Study: NCT05546073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced point-of-care technology
Description: The intervention consists of:~* focused lung ultrasound scan(FLUS)~* venous blood samples for leucocytes with 5-part differential count, creatinin, sodium, potassium, urea
Study: NCT04726059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Cord Stimulation
Description: Therapeutic TSCS will be delivered during ABT using a non-invasive central nervous system stimulator (TESCoN, SpineX Inc., CA, USA). Stimulation will involve charge balanced monophasic rectangular waveforms with 1.0-ms pulses, administered at 30 Hz, with a carrier frequency of 10 kHz and a current ranging from 10 to 130 mA.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM (low-intensity) Transcutaneous Spinal Cord Stimulation
Description: Ineffective stimulation will be administered at the same anatomical location as therapeutic TSCS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Activity-Based Therapy
Description: Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.~For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity-Based Therapy
Description: Using BWSTT, all participants (both arms) will train 3 times per week for 12 weeks with a target to reach 45 minutes of gait training in each session.~For gait training, the level of body weight support and speed of walking will be adjusted to allow the person to bear as much weight as possible while maintaining proper stance limb kinematics.
Study: NCT05628207

Intervention type: OTHER
Intervention: Observational
Description: There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.

Intervention type: OTHER
Intervention: Observational-control
Description: There is no intervention, the hospitals will not use the CDS system.
Study: NCT05899907

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
Study: NCT03859921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: Progesterone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with appearance similar to Dydrogesterone
Study: NCT05152810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation sessions
Description: * 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation sessions
Description: * 10 sessions daily from Monday to Friday (2 sessions/day, 15 minutes apart) during the 1st week = attack phase~* 2 weekly maintenance sessions the following week (S2), then 1 weekly maintenance session the following 4 weeks (S3, S4, S5 and S6) = maintenance phase

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluations
Description: Before the first stimulation session, just after the 10th session, at 6 weeks, at 12 weeks and at 24 weeks.~The assessment included the collection of AEs/EIGs, the TAC, the VAS on desire to smoke, the TCQ, the QSU, BDI-II (except at S1), the CO tester, GoNoGo, the PQI and the ISI.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Evaluations
Description: Before the first stimulation session, just after the 10th session, at 6 weeks, at 12 weeks and at 24 weeks.~The assessment included the collection of AEs/EIGs, the TAC, the VAS on desire to smoke, the TCQ, the QSU, BDI-II (except at S1), the CO tester, GoNoGo, the PQI and the ISI.
Study: NCT05932602

Intervention type: DEVICE
Intervention: Aveir DR Leadless Pacemaker System
Description: This study will utilize real-world data from patients implanted with the Aveir DR Leadless Pacemaker System. No device intervention is required in this study.

Intervention type: DEVICE
Intervention: Dual Chamber Transvenous Pacemaker
Description: This study will utilize real-world data from patients implanted with a dual-chamber transvenous pacemaker as a comparator to the Aveir DR LP system study arm. No device intervention is required in this study.
Study: NCT04232215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeraBEAT™
Description: A wireless Smart Fetal Ultrasound Doppler measuring device designed to be self-administered by the expectant mother throughout the different stages of pregnancy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler fetal heart rate monitor
Description: A hand-held ultrasound transducer that uses the Doppler Effect to provide an audible simulation of the heart beat and displays the number of beats per minute.
Study: NCT05297526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adapted children's book
Description: Tribe-specific children's book celebrating tribal culture with an embedded oral health message

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard informational brochure on children's oral health
Description: Informational brochure about children's oral health designed by the NIH for American Indian/Alaska Native parents.
Study: NCT04924478

Intervention type: BIOLOGICAL
Intervention: Mepolizumab
Description: Patients will be receiving this treatment as part of their standard clinical care
Study: NCT04607876

Intervention type: OTHER
Group type: OTHER
Intervention: Technological Facilitator
Description: See Enhanced Intervention Arm for full description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Risk factor assessment in first degree relative subjects and implementation of an education program for the randomized participants and their primary care provider.
Study: NCT05650853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound
Description: Examinations for observation of the pre, per and post-ejaculatory phases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urethroscopy
Description: Examinations for observation of the pre, per and post-ejaculatory phases
Study: NCT05670132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocardiac rehabilitation program
Description: Patients receiving a neurocardiac rehabilitation program for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: No intervention during the neurocardiac rehabilitation program
Study: NCT04471389

Intervention type: OTHER
Intervention: Incidence and risk factors of hypertension
Description: During the follow-up period, General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc). Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness, IMT, FMD) will be collected.

Intervention type: OTHER
Intervention: Incidence and risk factors of hypertension
Description: During the follow-up period, General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc). Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness, IMT, FMD) will be collected.
Study: NCT05896189

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: Computerized Cognitive Training-Global Stimulation Games
Description: The program will includes 8 non-speeded exercises that include spin-offs of such games as breaking hex, lineup four, battleship, gems swap, double klondike, solitaire, reversi, word search, and sudoku. These games are well matched for time on task, novelty, and progression across levels. These are strategy-based games without adaptive, speeded, or accuracy-based algorithms underlying their personalization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 2: Computerized Cognitive Training-Neuroplasticity Games
Description: Cognitive training exercises include Double Decision (targets visual speed of processing and useful field of view), Target Tracker (targets visuospatial working memory capacity), Visual Sweeps (targets speed of processing), Syllable Stacks (targets auditory memory), Eye for Detail (targets eye movement speed and visuo-spatial working memory), Mind Bender (targets mental flexibility), Divided Attention (a shape-color-pattern inhibitory control exercise that focuses on rapidly determining whether flashing colors, shapes, or patterns meet a pre-specified rule), Right Turn (targets spatial reasoning).
Study: NCT04997564

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir Alafenamide 25 MG
Description: All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 1 patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 1 patients will be discontinued TAF once daily therapy at the end of week 28 if no HBV reactivation occurs during treatment .

Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir / Velpatasvir
Description: All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 2 patients will be received TAF once daily for 64 weeks. In this study, after week 64.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir / Velpatasvir
Description: All the patients will use prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12 weeks. Group 2 patients will be received TAF once daily for 64 weeks. In this study, after week 64.
Study: NCT06094400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Participants in the intervention group will be furnished with a tablet incorporating a pre-installed Muse Meditation App and a set of headphones. They can choose their preferred immersive soundscape for the meditation session.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants allocated to the control group will similarly wear the portable EEG headband, but they will receive a rest session without any additional intervention
Study: NCT05536856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a new effervescent mixture 5-florouracil formula
Description: 30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil plain powder
Description: 30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
Study: NCT06547060

Intervention type: OTHER
Intervention: Exercise leggings
Description: The participants will wear two types of leggings (i.e., control leggings vs. leggings with shortened resistance bands) while performing the same exercise on two different days, respectively.
Study: NCT05017818

Intervention type: OTHER
Intervention: Observational retrospective data
Description: Non-intervention
Study: NCT05334277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 80mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 80mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib/Pemetrexed/Carboplatin
Description: Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed maintenance (500 mg/m2) every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Description: Furmonertinib 80mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) plus bevacizumab (7.5mg/kg) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) with bevacizumab (7.5mg/kg) maintenance every 3 weeks.
Study: NCT06219421

Intervention type: OTHER
Intervention: Clinical data reuse
Description: Clinical data reuse

Intervention type: OTHER
Intervention: Clinical data reuse
Description: Clinical data reuse
Study: NCT05403697

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized MAP
Description: Hemodynamic optimization beginning after general anesthesia induction, and ending at the 24th hour postoperatively, which consists in obtaining a mean arterial pressure (MAP) which is at least 90% of the usual MAP of the patient.
Study: NCT06337591

Intervention type: PROCEDURE
Intervention: VI-RADS
Description: Patients with suspected bladder cancer underwent multiparametric magnetic resonance imaging (mMRI) and vescical imaging reporting and data system (VI-RADS) score calculation. After trans-urethral resection of bladder (TURB), the results of biopsy were compared to the VI-RADS score to verify their concordance.
Study: NCT05052099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6, Atezolizumab and Bevacizumab
Description: All study medication is administered by intravenous (IV) infusion on Day 1 of each 14-day cycle:~• mFOLFOX6 consisting of Folinic acid (Leucovorin) 400 mg/m2 (D,L racemic form) or 200 mg/m2 (L-isomer form \[levo leucovorin\]), 5-fluorouracil (5-FU) 2400 mg/m2 and Oxaliplatin 85 mg/m2~combined with~* Atezolizumab 840 mg and~* Bevacizumab 10 mg/kg
Study: NCT05330793

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral probiotic
Description: an oral probiotic intervention with or without a novel ADP1 toothpaste

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral probiotic
Description: an oral probiotic intervention with or without a novel ADP1 toothpaste

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: placebo without Oral probiotic or toothpaste

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo without Oral probiotic or toothpaste
Study: NCT04868279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Interactive Nurse Support Program Based on Health Promotion Model
Description: Nursing education will be given on healthy behaviors such as nutrition, exercise, health responsibility and stress management according to the health promotion model. The researcher will make phone calls with the intervention group for 6 months (12 times in total), twice a month. During telephone interviews, individuals will be talking about the use of the website, the points that are not understood or need to be emphasized, their application of health promotion behaviors, the obstacles they experience during the application and the suggestions for this.
Study: NCT04816695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOC analysis
Description: VOC analysis in exhaled air with e-noses and mass spectrometry.
Study: NCT06593691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: Hot Pack, TENS, therapeutic ultrasound, and exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Hot Pack, TENS, therapeutic ultrasound, and exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment + multi-wave locked system laser treatment
Description: Hot Pack, TENS, therapeutic ultrasound, and exercise + multi-wave locked system laser treatment
Study: NCT06168045

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral tissue oxygenation and blood pressure measurement
Description: Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral tissue oxygenation and blood pressure measurement
Description: Measurement of cerebral tissue oxygenation with NIRS and blood pressure during immediate transition after birth
Study: NCT06554509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819 injection
Description: SHR-1819 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819 injection
Description: SHR-1819 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1819 injection
Description: SHR-1819 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo